Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
The DSM-5 Task Force’s handling of the ethical controversy over the bereavement exclusion demonstrates the need for more inclusive deliberative processes.
AMA J Ethics. 2017;19(2):192-198. doi:
10.1001/journalofethics.2017.19.2.pfor2-1702.
Workplace wellness programs contribute to the wellness movement by enlisting nontraditional health partners and influencing social determinants of health.
AMA J Ethics. 2016;18(4):393-398. doi:
10.1001/journalofethics.2016.18.4.nlit1-1604.